Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. has reported promising results from their Phase 2b PARADIGM ALS trial, indicating a significant slowdown in disease progression with their PrimeC treatment compared to placebo. The company’s financials show an 18% increase in R&D expenses due to expanded clinical programs and employee growth, offset by a 20% drop in general and administrative expenses, with an ending cash position of $2.6 million for 2023. These developments could potentially be impactful for patients with ALS, a market that is anticipated to grow by 24% by 2040.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
